Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
Alexander Klistorner, Yi Chai, Letizia Leocani, Philipp Albrecht, Orhan Aktas, Helmut Butzkueven, Tjalf Ziemssen, Focke Ziemssen, Jette Frederiksen, Lei Xu, Diego Cadavid, Helmut Butzkueven, Ray Garrick, Ludo Vanopdenbosch, Giancarlo Comi, Bernardo Sanchez Dalmau, Magnus Andersson, Gordon T Plant, Tim Matthews, Graeme Williams
CNS Drugs | ADIS INT LTD | Published : 2018
BACKGROUND: Multifocal visual evoked potential (MF-VEP) assesses a wider visual field than full-field VEP (FF-VEP) and potentially offers a more precise analysis of optic nerve injury and repair following optic neuritis. MF-VEP may offer advantages over FF-VEP as an endpoint in clinical trials of remyelinating therapies. OBJECTIVE: MF-VEP testing was used to study changes in visual pathways in 48% of RENEW [phase II, opicinumab (anti-LINGO-1; BIIB033) vs. placebo after first acute unilateral optic neuritis] participants. METHODS: This exploratory MF-VEP RENEW substudy compared mean outcomes at weeks 24 and 32 among participants in the intent-to-treat (ITT; n = 39; 72% female; mean age: 32.3 ..View full abstract
This study was supported by Biogen (Cambridge, MA, USA). Biogen also provided funding for medical writing support in the development of this paper and for the open access fee.